Addressing Disparities in Care in Women’s Reproductive Health

Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, provides a comprehensive background on uterine fibroids, explaining everything from clinical burden to symptoms.

Dr Al-Hendy discusses the impact UF has on a patient’s life and their typical patient journey through the healthcare system.

Maria Lopes, MD, discusses the economic burden of UF from a payer’s perspective, explaining direct and indirect costs associated with the condition.

Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, elaborates on risk factors for the development of UF.

Dr Ayman Al-Hendy details the shift from surgical options to medical therapy for patients with UF.

Dr Al-Hendy briefly explains how he determines treatment goals during initial workups for patients with UF.

Dr Al-Hendy highlights the oral GnRH receptor antagonists as first-line therapy for UF.

Dr Lopes discusses the typical payer challenges with managing UF treatment, including pain management.

Dr Maria Lopes provides an overview of common disparities seen when treating and maintaining women’s reproductive health and how these can be minimized.

Drs Lopes and Al-Hendy describe the unmet needs they see when treating patients with UF.

Dr Al-Hendy discusses what it takes to individualize UF treatment for each patient.

Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.